Skip to main content

Table 1 Examples of drugs approved for sale subsequently withdrawn from the market due to liver and cardiac toxicity

From: Human induced pluripotent stem cell-based microphysiological tissue models of myocardium and liver for drug development

Drug Year Reason for withdrawal
Terfenadine (Seldane) 1998 Risk of cardiac arrhythmias
Alpidem (Ananxyl) 1999 Rare serious hepatotoxicity
Grepafloxacin (Raxar) 1999 Prolonged QT interval
Troglitazone (Rezulin) 2000 Risk of hepatotoxicity
Trovafloxacin (Trovan) 2001 Risk of liver failure
Rofecoxib (Vioxx) 2004 Risk of myocardial infarction
Rosiglitazone (Avandia) 2010 Withdrawn in Europe because of increased risk of myocardial infarction and death. This drug continues to be available in the USA